Stay updated with breaking news from Utilization trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence - Randomized, controlled study of Buvidal weekly and monthly subcutaneous depot injections vs daily sublingual buprenorphine - The primary endpoint was met with statistically higher patient global satisfaction with the depot buprenorphine treatment - Improved outcomes were also reported for secondary endpoints, including decreased treatment burden and higher quality of life News provided by Share this article LUND, Sweden, May 10, 2021 /PRNewswire/ Camurus (NASDAQ STO: CAMX) announces today the publication in JAMA Network Open of results from a 24-week, randomized, controlled trial (DEBUT) comparing patient reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly buprenorphine depot injections (Buvidal ....